<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl7">
 <label>Table 7</label>
 <caption>
  <p>Antiviral activity of the most active stilbenoids.</p>
 </caption>
 <alt-text id="alttext0140">Table 7</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Compound</th>
    <th>Virus</th>
    <th>Target</th>
    <th>Activity (μM) and cell lines</th>
    <th>Ref.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">
     <bold>Hopeaphenol</bold>
    </td>
    <td align="left">Influenza A (A/NWS/33, H1N1)</td>
    <td align="left">NI</td>
    <td align="left">IC
     <sub>50</sub> = 6.4 μM on MDCK
    </td>
    <td align="left">Ito [
     <xref rid="bib33" ref-type="bibr">33</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Gnetin D</bold>
    </td>
    <td align="left">- A/PR/8/34 (H1N1)
     <break/>- A/Guangdong/243/72 (H3N2)
     <break/>- B/Jiangsu/10/2003
    </td>
    <td align="left">NI</td>
    <td align="left">IC
     <sub>50</sub> = 0.67 μg/mL (6.4 μM) (H3N2) on MDCK
    </td>
    <td align="left">Liu [
     <xref rid="bib34" ref-type="bibr">34</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>(+)-Vitisin A</bold>
    </td>
    <td align="left">Influenza A (A/PR/8/34, H1N1)-</td>
    <td align="left">↓ RANTES</td>
    <td align="left">EC
     <sub>50</sub> = 0.27 μM on Human alveolar epithelial A549
    </td>
    <td align="left">Huang [
     <xref rid="bib38" ref-type="bibr">38</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>2b</bold>
    </td>
    <td align="left">Influenza A (A/PR/8/34, H1N1)</td>
    <td align="left">Neuraminidase</td>
    <td align="left">EC
     <sub>50</sub> = 7.28 μg/mL (28 μM) on MDCK
    </td>
    <td align="left">Li [
     <xref rid="bib39" ref-type="bibr">39</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Resveratrol</bold>
    </td>
    <td align="left">MERS-CoV (HCoV-EMC/2012)</td>
    <td align="left">Interference with NF-κB pathway</td>
    <td align="left">Vero E6 (CRL-1586)</td>
    <td align="left">Lin [
     <xref rid="bib45" ref-type="bibr">45</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>5</bold>
    </td>
    <td align="left" rowspan="2">SARS-CoV</td>
    <td align="left">NI</td>
    <td align="left" rowspan="2">Vero E6</td>
    <td align="left" rowspan="2">Li [
     <xref rid="bib40" ref-type="bibr">40</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>6</bold>
    </td>
    <td align="left">NI</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Z-3, 4′, 5-trimethoxy stilbene (Z-TMS)</bold>
    </td>
    <td align="left">- HCV-1b replicon (FCA4), JFH1
     <break/>- HCV-2a (HCVcc)
    </td>
    <td align="left">↓ HCV NS5B</td>
    <td align="left">Hepatoma Huh7-derived (Huh7.5, GS5 and FCA4)
     <break/>FCA4-HCV
     <sup>+</sup>DCLK1
     <sup>+</sup>
    </td>
    <td align="left">Ngu yen [
     <xref rid="bib55" ref-type="bibr">55</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Vitisin B</bold>
    </td>
    <td align="left" rowspan="4">- HCV-2a (Rluc-J6/JFH1, J6/JFH1),
     <break/>- HCV-1b Con1 sequence (Bart79I)
     <break/>- HCVcc expressing an HCV NS5A-GFP fusion protein
    </td>
    <td align="left">↓ HCV NS3</td>
    <td align="left">EC
     <sub>50</sub> = 0.003 μM (2a genotype)
     <break/>EC
     <sub>50</sub> = 0.001 μM (1b genotype) on Huh7.5
    </td>
    <td align="left">Lee [
     <xref rid="bib57" ref-type="bibr">57</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>(+)-ϵ-Viniferin</bold>
    </td>
    <td align="left">↓ HCV NS3</td>
    <td align="left">EC
     <sub>50</sub> = 2.9 μM (2a genotype)
     <break/>EC
     <sub>50</sub> = 7.0 μM (1b genotype) on Huh7.5
    </td>
    <td align="left">Lee [
     <xref rid="bib58" ref-type="bibr">58</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>(±)-ϵ-VF</bold>
    </td>
    <td align="left">↓ HCV NS3</td>
    <td align="left">EC
     <sub>50</sub> = 9.3 μM (2a genotype) on Human hepatoma Huh7.5
     <break/>EC
     <sub>50</sub> = 1.7 μM (1b genotype)
    </td>
    <td align="left" rowspan="2">Lee [
     <xref rid="bib58" ref-type="bibr">58</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>(±)-ϵ-VF-5Ac</bold>
    </td>
    <td align="left">NI</td>
    <td align="left">EC
     <sub>50</sub> = 4.7 μM (2a genotype)
     <break/>EC
     <sub>50</sub> = 10.4 (1b genotype) ∗∗ on Huh7.5
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>PNR-4-44</bold>
    </td>
    <td align="left" rowspan="2">DENV-2-induced CPE</td>
    <td align="left">↓ RNA viral synthesis</td>
    <td align="left">EC
     <sub>50</sub> = 8.12 nM (0.00812 μM)
    </td>
    <td align="left" rowspan="2">Han [
     <xref rid="bib66" ref-type="bibr">66</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>PNR-5-02</bold>
    </td>
    <td align="left">↓ RNA viral synthesis and host cell factors interference</td>
    <td align="left">EC
     <sub>50</sub> = 7.22 nM (0.00722 μM)
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Pterostilbene</bold>
    </td>
    <td align="left">HIV-1</td>
    <td align="left">↓ integrase, prevents CD4 T cells infection</td>
    <td align="left">Activated T and transformed T Jurkat (clone E6), IL-4 treated CD4 T and Resting CD4</td>
    <td align="left">Chan [
     <xref rid="bib72" ref-type="bibr">72</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Leachianol G</bold>
    </td>
    <td align="left">HIV-1</td>
    <td align="left">↓ integrase</td>
    <td align="left">293T</td>
    <td align="left">Pflie ger [
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Resveratrol</bold>
    </td>
    <td align="left" rowspan="2">HIV-1</td>
    <td align="left">Prevents CD4 T cells infection, synergism with RNR inhibitors</td>
    <td align="left">EC
     <sub>50</sub> = 4.37 μg/mL (19 μM) on C8166
    </td>
    <td align="left" rowspan="2">Lin [
     <xref rid="bib74" ref-type="bibr">74</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>14</bold>
    </td>
    <td align="left">NI</td>
    <td align="left">EC
     <sub>50</sub> = 84.77 μg/mL (172 μM) on C8166
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Dibalanocarpol</bold>
    </td>
    <td align="left" rowspan="2">HIV-1</td>
    <td align="left">NI</td>
    <td align="left">EC
     <sub>50</sub> = 46 μM on CEM-SS
    </td>
    <td align="left" rowspan="2">Dai [
     <xref rid="bib75" ref-type="bibr">75</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Balanocarpol</bold>
    </td>
    <td align="left">NI</td>
    <td align="left">EC
     <sub>50</sub> = 20 μM on CEM-SS
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>DIDS</bold>
    </td>
    <td align="left" rowspan="2">HIV-1 strain RF
     <break/>HIV-1 strain GB8
    </td>
    <td align="left" rowspan="2">Binding to coreceptor CD4</td>
    <td align="left">IC
     <sub>50</sub> = 20 μM on JM
    </td>
    <td align="left" rowspan="2">Cardin [
     <xref rid="bib76" ref-type="bibr">76</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>H</bold>
     <sub>
      <bold>2</bold>
     </sub>
     <bold>DIDS</bold>
    </td>
    <td align="left">IC
     <sub>50</sub> = 40 μM on JM
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>NSC34931 (stilbenavir)</bold>
    </td>
    <td align="left">HIV-1</td>
    <td align="left">↓ Integrase</td>
    <td align="left">IC
     <sub>50</sub> = 0.32 μM
     <break/>EC
     <sub>50</sub> = 3.07 μM on MT4-LTR-eGFP
    </td>
    <td align="left" rowspan="2">Aknin [
     <xref rid="bib77" ref-type="bibr">77</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>NSC34933</bold>
    </td>
    <td align="left">HIV-1</td>
    <td align="left">↓ Integrase</td>
    <td align="left">IC
     <sub>50</sub> = 1.1 μM
     <break/>EC
     <sub>50</sub> = 0.60 μM on MT4-LTR-eGFP
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>CGA137053</bold>
    </td>
    <td align="left">HIV-1</td>
    <td align="left">Binding to Tat protein</td>
    <td align="left">EC
     <sub>90</sub> = 0.5–5 μM on Human leucocytes (PBL) and macrophages
    </td>
    <td align="left">Hamy [
     <xref rid="bib82" ref-type="bibr">82</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>23a</bold>
    </td>
    <td align="left">HIV-1</td>
    <td align="left">NI</td>
    <td align="left">EC
     <sub>50</sub> = 8.8 μM) on 293T
    </td>
    <td align="left">Clouser [
     <xref rid="bib70" ref-type="bibr">70</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>M8</bold>
    </td>
    <td align="left">HIV-1 NL 4–3 or BaL variants</td>
    <td align="left">↓ viral attachment</td>
    <td align="left">EC
     <sub>50</sub> = 0.29–1.69 μM on MT-4 and TZM-bl cells
    </td>
    <td align="left">Han [
     <xref rid="bib87" ref-type="bibr">87</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>28</bold>
    </td>
    <td align="left">HNV</td>
    <td align="left">↓ RNA viral replication</td>
    <td align="left">EC
     <sub>50</sub> = 2.43 μM on HG23 cells
    </td>
    <td align="left">Harmalkar [
     <xref rid="bib91" ref-type="bibr">91</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Resveratrol</bold>
    </td>
    <td align="left" rowspan="2">HRV1B
     <break/>CVB3
     <break/>EV71
    </td>
    <td align="left">NI</td>
    <td align="left">IC
     <sub>50</sub> = 29.7 μM (HRV1B) on Hela
    </td>
    <td align="left" rowspan="2">Oh [
     <xref rid="bib94" ref-type="bibr">94</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>
      <italic>cis</italic>-resveratrol
     </bold>
    </td>
    <td align="left">NI</td>
    <td align="left">IC
     <sub>50</sub> = 12.2 μM (CVB3)
     <break/>IC
     <sub>50</sub> = 37.6 μM (EV71) on Vero
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Vadelianin</bold>
    </td>
    <td align="left">EV 7, 13 and 19 serotypes</td>
    <td align="left">NI</td>
    <td align="left">IC
     <sub>50</sub> = 0.0036 nM (0.0036 • 10
     <sup>−3</sup> μM) on Human rhabdomyosarcoma (RD)
    </td>
    <td align="left">Segun [
     <xref rid="bib95" ref-type="bibr">95</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Kuwanon X</bold>
    </td>
    <td align="left">HSV-1 (15577 and clinical strains)
     <break/>HSV-2 (333 strains)
    </td>
    <td align="left">↓ viral adsorption, penetration, proteins, DNA biosynthesis, NF-κB pathway</td>
    <td align="left">IC
     <sub>50</sub> = 2.2 μg/mL (3.77 μM) (15577 strain)
     <break/>IC
     <sub>50</sub> = 1.5 μg/mL (2.57 μM) (clinical strain)
     <break/>IC
     <sub>50</sub> = 2.5 μg/mL (4.29 μM) (333 strain) on Vero and Hela
    </td>
    <td align="left">Ma [
     <xref rid="bib23" ref-type="bibr">23</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>(−)-hopeaphenol</bold>
    </td>
    <td align="left" rowspan="2">HSV-1
     <break/>HSV-2
    </td>
    <td align="left" rowspan="2">NI</td>
    <td align="left">IC
     <sub>50</sub> = 2.8 μM (HSV-1)
     <break/>IC
     <sub>50</sub> = 6.4 μM (HSV-2) on MDCK
    </td>
    <td align="left" rowspan="2">Ito [
     <xref rid="bib33" ref-type="bibr">33</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Shoreaketone</bold>
    </td>
    <td align="left">IC
     <sub>50</sub> = 2.8 μM (HSV-1)
     <break/>IC
     <sub>50</sub> = 6.8 μM (HSV-2) on MDCK
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Vaticaffinol</bold>
    </td>
    <td align="left">HSV-1 (strain 17)
     <break/>HSV-2 strain G (VR-734)
    </td>
    <td align="left">Promotes ROS production</td>
    <td align="left">IC
     <sub>50</sub> = 3.2 μM (HSV-2) on HeLa, Vero, and H1299
    </td>
    <td align="left">Chen [
     <xref rid="bib103" ref-type="bibr">103</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Oxyresveratrol</bold>
    </td>
    <td align="left">HSV-1 (7401H and KOS)
     <break/>HSV-2 (Baylor 186) TK-deficient HSV-1 strain (B2006 strain) and PAA-resistant strain
    </td>
    <td align="left">Inhibition of late viral proteins</td>
    <td align="left">IC
     <sub>50</sub> = 19.8 μg/mL (81.0 μM) (7401H)
     <break/>IC
     <sub>50</sub> = 24 μg/mL (98.2 μM) (KOS)
     <break/>IC
     <sub>50</sub> = 18.7 μg/mL (76.6 μM) (Baylor 186) on Vero (ATCC CCL81)
    </td>
    <td align="left">Chuanasa [
     <xref rid="bib105" ref-type="bibr">105</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>NI= Not Identified.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
